Lebrikizumab
Lebrikizumab
Definition
A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. Lebrikizumab binds to IL-13 and inhibits IL-13-mediated pathways. IL-13, a cytokine mainly secreted by type 2 helper T cells, plays a key role in the induction of allergic inflammation.
Also known as Anti-IL-13 Humanized Monoclonal Antibody TNX-650, Immunoglobulin G4, Anti-(Human Interleukin 13) (Human-Mouse Monoclonal MILR1444a Gamma-4-Chain), Disulfide with Human-Mouse Monoclonal MILR1444a Kappa-Chain, Dimer, LEBRIKIZUMAB, MILR1444A, Monoclonal Antibody TNX-650, PRO301444, TNX-650 — per NCIT
Also identified as
- ATC D11AH10 per RXNORM
- NCIT NCIT:C87767 per NCIT
- SCTID 1351535000 per RXNORM
- UNII U9JLP7V031 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Atopic eczema | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Skin of body | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.